Burlington, Ontario--(Newsfile Corp. - April 1, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") announced today that as contemplated in the secured convertible notes (the " Notes ") previously issued on its private placement financing (the " Financing "), and consistent with prior quarters, the Company intends to issue common shares (" Common Shares ") in satisfaction of the accrued interest... Read More

Burlington, Ontario--(Newsfile Corp. - February 18, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") today announced that it plans to complete an equity private placement financing (the " Financing ") for up to $5,000,000 of gross proceeds, consisting of up to 20,833,333 common shares (the " Common Shares ") at a price of $0.24 per Common Share. The Company will be engaging Meadowbank Asset... Read More

Burlington, Ontario--(Newsfile Corp. - January 28, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (RDT), a Canadian biotechnology company working with an international company in oral nicotine products, is pleased to announce the expansion of their collaboration through the continuation of the exclusive pre-commercialization agreement. This agreement aims to finalize the development of innovative, market-ready products... Read More

Burlington, Ontario--(Newsfile Corp. - January 27, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") today announced that further to its press release dated December 9, 2024 (the " Initial Press Release "), announcing a proposed debt settlement (the " Shares for Debt Transaction ") with certain of its creditors (the " Creditors ") to issue an aggregate of up to 1,600,000 common shares (the "... Read More

Burlington, Ontario--(Newsfile Corp. - January 16, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") is pleased to announce that it has completed its previously announced shares for debt transaction to issue common shares (the " Debt Shares ") to its non-management directors (the " Directors ") in exchange for the cancellation of directors' fees owing. Each of the five Directors was owed $10,000... Read More

Burlington, Ontario--(Newsfile Corp. - January 7, 2025) - Rapid Dose Therapeutics Corp . (CSE: DOSE) (" RDT " or the " Company ") announced today that as contemplated in the secured convertible notes (the " Notes ") previously issued on its private placement financing (the " Financing "), and consistent with prior quarters, the Company intends to issue common shares (" Common Shares ") in satisfaction of the accrued interest... Read More

Burlington, Ontario--(Newsfile Corp. - December 24, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") announces that it has agreed with its non-management directors (the " Directors ") to issue common shares (the " Debt Shares ") to such Directors in exchange for the cancellation of director fees owing. Each of the five Directors is owed $10,000 in director fees for each of the fiscal quarters... Read More

Burlington, Ontario--(Newsfile Corp. - December 10, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") today announced that it plans to complete an equity private placement financing (the " Financing ") for up to $6,000,000 of gross proceeds, consisting of up to 24,000,000 units (the " Units ") at a price of $0.25 per Unit. Each Unit will consist of one (1) Common Share and one (1) Common Share... Read More

Burlington, Ontario--(Newsfile Corp. - December 5, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company "), a Canadian biotechnology company, is pleased to announce that it has filed a patent application for its Lidocaine Oral Thin Film Strip, with the Canadian Intellectual Property Office ("CIPO"). Dentists commonly perform dental procedures using anesthesia administered through injection by needle,... Read More

Burlington, Ontario--(Newsfile Corp. - October 30, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") is pleased to announce that it has closed a second and final tranche of its previously announced equity private placement financing (the " Financing ") for aggregate gross proceeds of $542,000. The proceeds of the Financing will be used for research and development, capital expansion, repayment of... Read More

Burlington, Ontario--(Newsfile Corp. - October 1, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") announced today that as contemplated in the secured convertible notes (the " Notes ") previously issued on its private placement financing (the " Financing "), the Company intends to issue common shares (" Common Shares ") in satisfaction of the accrued interest payable on September 30, 2024 under... Read More

Burlington, Ontario--(Newsfile Corp. - September 16, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") today announced that further to its press release dated August 7, 2024, regarding a proposed equity private placement financing (the " Financing "), the Company has received an extension from the Canadian Securities Exchange allowing it to close the Financing on or before October 29, 2024. This... Read More

Burlington, Ontario--(Newsfile Corp. - July 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") is pleased to announce that it has closed a first tranche of its previously announced equity private placement financing (the " Financing ") for aggregate gross proceeds of $309,000. The proceeds of the Financing will be used for research and development, capital expansion, repayment of debt and... Read More

Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") announced today that as contemplated in the secured convertible notes (the " Notes ") previously issued on its private placement financing (the " Financing "), the Company intends to issue common shares (" Common Shares ") in satisfaction of the accrued interest payable on June 30, 2024 under the... Read More

Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company "), is pleased to announce the filing of its financial results for the year ended February 29, 2024. Mark Upsdell, Chairman and Chief Executive Officer, stated, "Over the past several years, our product roadmap has expanded from our Nutraceutical business to complementary markets such as Pharmaceutical,... Read More

Burlington, Ontario--(Newsfile Corp. - June 25, 2024) - Rapid Dose Therapeutics Corp . (" RDT " or the " Company ") trading on the Canadian Securities Exchange ("CSE") under the symbol DOSE is pleased to announce the recent award of a Mitacs Accelerate grant, with a value of $30,000 in May 2024 in addition to $55,000 in 2023, to continue the development of Thin Polymer Films for Vaccine Delivery Project, led by Prof. Alex... Read More

Burlington, Ontario--(Newsfile Corp. - June 19, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") today announced that further to its press release dated May 8, 2024, regarding a proposed equity private placement financing (the " Financing "), the Company has received an extension from the Canadian Securities Exchange allowing it to close the Financing on or before August 8, 2024. This previously... Read More

Burlington, Ontario--(Newsfile Corp. - May 29, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (" RDT " or the " Company ") announces its collaboration in the National Football League (NFL) – funded clinical trial program entitled "Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in Contact Sports" led by Dr. J. Patrick Neary and researchers at the University of... Read More